Skip to main content

Table 1 Characteristics of the selected patients at admission (n = 12)

From: Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer

Variables Values
Age, yrs 68.8 ± 6.9
Gender, male/female 9/3
Types of NSCLC, adeno/squamous/NOS 8/3/1
Types of ICI, nivolumab/pembrolizumab 7/5
Duration of ICI use, mo 5.0 ± 4.1
mMRC dyspnea grade, 0/1/2/3/4 3/2/5/1/1
Grade of pneumonitis, 1/2/3/4 2/7/3/0
  1. Values are expressed as mean ± standard deviation or by the actual number
  2. Grade of pneumonitis was assessed according to CTCAE v5.0
  3. CTCAE, Common Terminology Criteria for Adverse Events; ICI, immune checkpoint inhibitor; mMRC, modified Medical Research Council; NSCLC, non-small cell lung cancer; NOS, not otherwise specified